Skip to main content
. 2014 Jun 13;12:50. doi: 10.1186/1477-7827-12-50

Figure 9.

Figure 9

Interactions between MEK, c-Myc, c-Fos and growth factors. The effects of EGF and TNF-alpha are mediate via the MEK-pathway. Selumetinib and other MEK/ERK inhibitors are being primarily developed and studied for cancer treatment. However, the role of the MEK/ERK-pathway in endometriosis suggests that these therapeutic strategies may lend themselves equally well to this disease.